Trial Profile
Comparison of Effectiveness of Glulisine and Lispro in Decreasing Post-Prandial Hyperglycemia in a Real-World Setting
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glulisine (Primary) ; Insulin lispro (Primary) ; Insulin aspart
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 07 May 2013 Results presented at the 2013 Annual Meeting of the Pediatric Academic Societies.
- 31 Jan 2013 Actual end date Aug 2012 added as reported by ClinicalTrials.gov.
- 13 Jun 2012 Trial company (Sanofi-Aventis), lead trial centre, planned patient no 188 and trial investigator added as reported by ClinicalTrials.gov.